

PRODUCT INFORMATION



GS967

Item No. 18376

CAS Registry No.: 1262618-39-2

Formal Name: 6-[4-(trifluoromethoxy)phenyl]-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridine

MF: C₁₄H₇F₆N₃O

FW: 347.2


Purity: ≥98%

UV/Vis.: λ_{max}: 247 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

GS967 is supplied as a crystalline solid. A stock solution may be made by dissolving the GS967 in the solvent of choice. GS967 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of GS967 in these solvents is approximately 12, 20, and 25 mg/ml, respectively.

GS967 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, GS967 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. GS967 has a solubility of approximately 0.3 mg/ml in a 1:2 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Inhibition of cardiac late sodium current (late I_{Na}) is a strategy to suppress arrhythmias and sodium-dependent calcium overload associated with myocardial ischemia and heart failure. GS967 is a selective inhibitor of late I_{Na} that has been shown to suppress experimentally induced arrhythmias in rabbit myocytes and hearts.¹ It can inhibit *A. sulcata* toxin II-induced late I_{Na} in ventricular myocytes and isolated hearts with IC₅₀ values of 0.13 and 0.21 μM, respectively.¹ GS967 causes minimal inhibition of the delayed-rectifier potassium current nor does it affect L- or T-type calcium channel currents, sodium-calcium exchanger currents, or a panel of 162 receptors, ion channels, transporters, and enzymes.¹

Reference

1. Belardinelli, L., Liu, G., Smith-Maxwell, C., *et al.* A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias. *J. Pharmacol. Exp. Ther.* **344**(1), 23-32 (2013).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/02/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM